Objective/Introduction
• Fuelled by dietary changes, increased sedentary lifestyles, and greater urbanisation in the Asia-Pacific region, there has been an increase in the number of people suffering from T2D (type 2 diabetes).
Understanding the impact of ethnicity on the efficacy and safety of anti-diabetes drugs is necessary to optimise drug development strategies and shorten the time-lag between drug approval in the West and in Asia. The purpose of this study was to examine the role of ethnicity on treatment outcomes in T2D clinical trials, using liraglutide as an example.
Conclusion
Clear differences between Asian and non-Asian studies highlight the need for studies specifically designed to elucidate the effect of the ethnic factor on the efficacy and safety outcomes of anti-diabetes drugs. Ethnicity is constituted by intrinsic and extrinsic factors, both of which should be evaluated in order to better predict and optimise the efficacy of treatment therapies across patient populations. 
Methods
• Targeted searches were performed in PubMed and clinicaltrials.gov to identify relevant studies. To be included in our analysis the study had to: be a completed double-blind phase III clinical trial of liraglutide; include patients with T2D; and report ΔHbA 1c as an outcome. The included studies were divided by country of study, followed by subsequent extraction of relevant baseline characteristics and outcomes to be compared. The study design and eligibility criteria applied were also compared between the clinical trials conducted in Asian and nonAsian countries.
Results
• Three Asian and five non-Asian studies satisfied all inclusion criteria. Asian study populations tended to have a lower body mass index than their non-Asian comparators, which was reflected in the lower treatment dosages (Figure 1 ). Moreover, there was a trend towards longer duration of disease in Asian study populations ( Figure  2 ). Substantial heterogeneity was observed between the clinical trial designs, including variable treatment durations, choice of comparator drug and dosages, and the use of mono-or combination therapies. Study subject eligibility criteria were, on the whole, comparable between the Asian and non-Asian studies, with the exception of the maximum permitted BMI: 35 kg/m Japan) and one North American study (NCT00294723: Garber et al. 2008, 3 US/Mexico) were identified as sufficiently similar to each other, with similar treatment durations, treatment regimens (monotherapy) and dosage frequencies, to non-directly compare the efficacy and safety outcomes of liraglutide in Asian and non-Asian populations.
Comparison of study designs
• Both the Japanese study and the North American study were randomised, double-blind, double-dummy, parallel-group phase III trials of liraglutide vs the active comparator sulfonylurea drugs glibenclamide and glimepiride respectively. In the study by Seino et al., the 24-week double-blind period was followed by a 28-week openlabel extension period, 2 resulting in efficacy and safety data at week 52. The North American study, on the other hand, was double-blind throughout the 52-week trial period.
• Furthermore, whilst the Japanese study included a 4-6 week long oral anti-diabetic drugs (OAD) washout period prior to randomisation, this washout period was absent in the North American study.
• The dosage in the Japanese study was substantially lower than the dosages in the North American study (0.9 mg/day vs. 1.2 mg/day and 1.8 mg/day respectively). Lower dosages were generally observed in Asian studies and in our analysis we assumed that these dosages had been optimised to the pharmacokinetics of the population in question. 4, 5 Both studies employed dose escalation to initiate the treatment. The treatment was administered subcutaneously once daily.
Comparison of baseline characteristics
• Upon comparison of the baseline characteristics of Seino et al. 2010 and Garber et al. 2008 , a number of differences were evident (Figure 2 ): -The mean BMI and weight of the Japanese subjects were much lower than the North American subjects -The duration of disease was longer in Japan -The percentage of subjects previously treated with OAD therapy was higher in the Japanese study -The North American subjects were on average younger than their Japanese counterparts 
Treatment efficacy
• Due to the open-label extension period in the last 28 weeks of the Japanese study, we decided to compare HbA 1c levels at week 24, when both the Japanese study and the North American study were double-blind.
• In the Japanese study, HbA 1c levels decreased by 1.93 percentage points in the 0.9 mg/day liraglutide group after 24 weeks. In the North American study, HbA 1c levels decreased by 1.0 percentage point with liraglutide 1.2 mg/day and 1.20 percentage points with liraglutide 1.8 mg/day. This non-direct comparison suggests that liraglutide is more effective in lowering HbA 1C levels in Asian patients than in North American patients ( Figure  3 ). 
Safety
• The most common treatment-emergent adverse events (TEAEs) by system organ class were the same in both the Japanese and the North American studies ( Figure  4 ). 7.5% of the subjects were withdrawn from the Japanese study after 52 weeks due to AEs. The same figures for the North American were 2.0% (1.2 mg/day) and 0.4% (1.8 mg/day). 
Discussion
• The pathophysiology of T2D includes lack of insulin secretion from beta-cells, weight gain and loss of insulin sensitivity in target tissues over time. The main cause for hyperglycaemia in Japanese patients is thought to be a lack of insulin secretion from beta-cells rather than insulin resistance; the opposite is true for Caucasian patients. 6, 7 Liraglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist) that stimulates insulin secretion from beta-cells and as such addresses the lack of insulin secretion rather than insulin resistance.
• The role of the ethnic factor is complicated by the ambiguous definition of ethnicity. In our case, we used the term 'ethnicity' to refer to the genetic differences between people of different ethnic origin, which can be thought of as the intrinsic ethnic factor. However, in addition to the intrinsic component there is an extrinsic ethnic factor that comprises multiple characteristics associated with a particular ethnic group, for example:
-Dietary habits -Levels of physical activity -Prevalence of concomitant medications, including alternative medicine -Compliance to treatment regimens -Susceptibility to the placebo effect • Our study highlights the challenge of making a quantitative assessment of the impact of ethnicity when comparing the outcomes of clinical trial from Asian and non-Asian countries. The differences in study design, including the treatment duration, the choice of comparator drug, the dosage and the use of mono-or combination therapies, prevented the outcomes from being directly comparable.
Study design
• Asian studies often act as complementary studies to achieve market authorisation of drugs already approved in other regions, particularly in the West. Therefore, this may help to explain the shorter study durations observed, as these studies only need to demonstrate safety and efficacy at critical time-points. Consequently, there are few Asian studies that can be compared with the long-term clinical trials carried out in Europe or North America, where the initial market authorisation was issued.
Baseline characteristics
• When comparing the studies of Seino et al. and Garber et al., it was noted that the duration of disease was longer in Japan, which is consistent with the higher mean age of the subjects. This suggests that T2D started around the same age in both study populations, and that the Japanese subjects had a later stage of disease progression.
Efficacy and safety outcomes
• Liraglutide significantly reduced HbA 1c levels at week 24 in both studies: the Japanese study was associated with a larger decrease in HbA 1c levels (1.93 percentage points) compared to the North American study (1.2 mg/ day: 1.0 percentage point; 1.8 mg/day: 1.20 percentage points). One explanation for this difference could be the different pathophysiologies of the Asian and non-Asian study populations (insulin-deficient and insulin-resistant, respectively). However, additional trials are required to investigate this hypothesis and to test whether these differences are significant.
• The safety profile of liraglutide was similar in the two studies, with a comparable number of TEAEs. On the other hand, treatment discontinuation due to AEs was more frequent in the Japanese study (7.5% vs. 2.0% and 0.4%). It is very difficult to draw any conclusions from these observations without understanding how the TEAEs were defined and the criteria for treatment discontinuation in the two trials.
The importance of understanding the impact of ethnicity
• Our study was unable to accurately assess the impact of intrinsic ethnicity in the treatment of T2D, due to a number of confounding factors. Case-control genetic studies have been recognised as the best method to understand this question, 8 and indeed such studies have been carried out, for example to assess the role of genetics in the development of coronary complications in T2D.
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• Despite these difficulties in understanding the ethnic factor in the efficacy and safety outcomes of anti-diabetes drugs, it is still important that we gain an understanding of the topic and conduct studies to attribute differences in ethnicity to the intrinsic and extrinsic ethnic factors respectively. In addition, it will be important to carry out studies across Asia, given the variability in extrinsic ethnic factors, such as the healthcare landscape, as well as intrinsic factors of different Asian populations.
• It is possible that there are drugs unsuitable for European and North American populations (where drugs are usually first studied), but suitable for Asian populations. However, studies on such drugs are likely to be discontinued upon failure in European or North American trials, even though they could potentially benefit Asian patients due to genetic differences. 
